Gilead Sciences, Inc. $GILD is Sector Gamma AS’s 9th Largest Position

Sector Gamma AS lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 147,239 shares of the biopharmaceutical company’s stock after buying an additional 20,239 shares during the period. Gilead Sciences comprises 4.1% of Sector Gamma AS’s investment portfolio, making the stock its 9th largest position. Sector Gamma AS’s holdings in Gilead Sciences were worth $16,344,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of GILD. Csenge Advisory Group boosted its stake in shares of Gilead Sciences by 319.0% in the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock valued at $2,375,000 after purchasing an additional 16,288 shares in the last quarter. Railway Pension Investments Ltd lifted its stake in Gilead Sciences by 3.1% in the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after purchasing an additional 42,200 shares during the last quarter. TriaGen Wealth Management LLC purchased a new stake in Gilead Sciences during the third quarter valued at about $1,274,000. Invesco Ltd. grew its stake in shares of Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after buying an additional 3,394,330 shares during the last quarter. Finally, Sivik Global Healthcare LLC increased its holdings in shares of Gilead Sciences by 25.0% in the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after buying an additional 10,000 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $135.93 on Friday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company has a market cap of $168.65 billion, a PE ratio of 21.07, a P/E/G ratio of 0.71 and a beta of 0.33. The business has a 50 day moving average of $123.98 and a 200 day moving average of $118.68. Gilead Sciences, Inc. has a 52 week low of $92.26 and a 52 week high of $136.30.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s payout ratio is currently 48.99%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on GILD shares. Sanford C. Bernstein set a $135.00 target price on Gilead Sciences and gave the company an “outperform” rating in a report on Monday, December 29th. Scotiabank initiated coverage on Gilead Sciences in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price objective for the company. Needham & Company LLC increased their price objective on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Wolfe Research restated an “outperform” rating and issued a $150.00 target price on shares of Gilead Sciences in a report on Monday, December 15th. Finally, Rothschild & Co Redburn lifted their target price on shares of Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $133.52.

Insider Buying and Selling

In other news, EVP Deborah H. Telman sold 53,646 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the transaction, the executive vice president owned 43,676 shares of the company’s stock, valued at approximately $5,365,596.60. This represents a 55.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $122.00, for a total value of $366,000.00. Following the completion of the transaction, the chief financial officer owned 153,503 shares of the company’s stock, valued at approximately $18,727,366. The trade was a 1.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 141,757 shares of company stock valued at $17,569,112 over the last quarter. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.